OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
종목 코드 OABIW
회사 이름OmniAb Inc
상장일Oct 09, 2020
CEOMr. Matthew William (Matt) Foehr
직원 수- -
유형Company Warrant
회계 연도 종료- -
주소5980 Horton Street
도시EMERYVILLE
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호94608
전화15102507800
웹사이트https://www.omniab.com/
종목 코드 OABIW
상장일Oct 09, 2020
CEOMr. Matthew William (Matt) Foehr
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음